NCT07882576Not yet recruiting
A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma
WW-CLARITY: Real-world Characteristics, Treatments, and Outcomes of Treatment-Naïve (TN) Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the UK, France, Canada, and Brazil
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 532 (estimated)
- First submitted
- 28 Sept 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07882576
What you commit to
- Study type: Observational
- Planned participants: 532
- From 30 Nov 2026 to the primary completion date, 30 Jan 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who were treated for another primary cancer diagnosis documented less than 5 years prior to the index event.
- Patients who received systemic treatment for LDGCB prior to the index event.
- Patients who received palliative care as first-line treatment.
- Patients who participated in a clinical trial after the index date (i.e. who received treatment for LDGCB as part of a clinical trial)
Who the study is looking for
- Patients with newly diagnosed LDGCB prior to the index date during the study identification period (1 January 2020 to 1 July 2024) in registries/databases in Brazil, Canada, France and the United Kingdom.
- Patients aged ≥ 18 years at the time of their first diagnosis of LDGCB.
- Patients who started eligible first-line systemic therapy during the study identification period (1 January 2020 to 1 July 2024).
- Identify patients who started palliative care during the study identification period (1 January 2020 to 31 December 2024).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UNICAMP Coordinator of this site? Confirm its status | Campinas | Brazil | Unknown status |
| Hospital Erasto Gaertner Coordinator of this site? Confirm its status | Curitiba | Brazil | Unknown status |
| Hospital Municipal da Vila Santa Catarina Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| AC Camargo Cancer Center Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Hospital Israelita Albert Einstein Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.